MEANING: These results did not support the interpretation of ERBB2-low as a distinct biologic subtype of breast cancer.IMPORTANCE: It is unclear whether ERBB2-low breast cancer should be considered an individual biologic subtype distinct from ERBB2-0 breast...
Rimm begins by clarifying that the IHC test for HER2 is a companion diagnostic rather than a standard diagnostic test, meaning it is specifically used to determine eligibility for certain therapies. In this case, the companion diagnostic is primarily associated with...
HER2 antagonists remain the cornerstone of therapy for patients with HER2-positive breast cancer. This study introduces a novel small-molecule inhibitor of
MEANING: Use of the current ERBB2 assays as a companion diagnostic test for trastuzumab deruxtecan may result in misassignment of patients for treatment. IMPORTANCE: Trastuzumab deruxtecan (T-DXd) has shown efficacy in patients with breast cancer with ERBB2 immunohistochemistry (IHC) scores of 1...
MEANING: These findings suggest that the chemotherapy-free anti-ERBB2 strategy is an option as first-line treatment in some patients with ERBB2-positive metastatic breast cancer. IMPORTANCE: In ERBB2 (formerly HER2)-positive metastatic breast cancer (MBC), combining trastuzumab and pertuzumab with ...
MEANING: These findings suggest that the chemotherapy-free anti-ERBB2 strategy is an option as first-line treatment in some patients with ERBB2-positive metastatic breast cancer. IMPORTANCE: In ERBB2 (formerly HER2)-positive metastatic breast cancer (MBC), combining trastuzumab and pertuzumab with ...
MEANING: These findings suggest that the chemotherapy-free anti-ERBB2 strategy is an option as first-line treatment in some patients with ERBB2-positive metastatic breast cancer. IMPORTANCE: In ERBB2 (formerly HER2)-positive metastatic breast cancer (MBC), combining trastuzumab and pertuzumab with ...
1. What is the impact of HER2 levels in HER2-positive metastatic BC patients treated with standard therapy? 2. Is there room for targeting HER2-negative tumors with low HER2 expression (meaning cases with IHC score 1+ or 2+ not amplified by FISH)? Starting from the first question, the le...
Findings Overall, 17 of 20 brain metastases in this study retained the PAM50 subtype of the primary tumor; yet, clinically actionable gains are common, with approximately 20% of ERBB2/HER2-negative primary tumors switching to ERBB2/HER2-positive. Meaning Breast cancer brain metastases commonly acq...
For example, patients who have residual disease after HER2-directed preoperative therapy are at a higher risk for recurrence, meaning escalating therapy may be beneficial. However, patients who achieve pathological complete response (pCR) after preoperative therapy may be able to de-escalate therapy. ...